What is the price-to-earnings ratio of ImmuCell?
The price-earnings ratio of ImmuCell is currently 2.22.
ImmuCell P/S 2024
ImmuCell P/S
2.22
Ticker
ICCC
ISIN
US4525253062
WKN
885825
As of Jul 31, 2024, ImmuCell's P/S ratio stood at 2.22, a -35.47% change from the 3.44 P/S ratio recorded in the previous year.
The ImmuCell P/S history
ImmuCell Aktienanalyse
What does ImmuCell do?
ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding ImmuCell's P/S Ratio
ImmuCell's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing ImmuCell's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating ImmuCell's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in ImmuCell’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about ImmuCell stock
How has the price-earnings ratio of ImmuCell changed compared to last year?
The price-to-earnings ratio of ImmuCell has increased by -35.47% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of ImmuCell high compared to other companies?
Yes, the price-to-earnings ratio of ImmuCell is high compared to other companies.
How does an increase in the price-earnings ratio of ImmuCell affect the company?
An increase in the price-earnings ratio of ImmuCell would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of ImmuCell affect the company?
A decrease in the price-earnings ratio of ImmuCell would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of ImmuCell?
Some factors that influence the price-earnings ratio of ImmuCell are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does ImmuCell pay?
Over the past 12 months, ImmuCell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuCell is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmuCell?
The current dividend yield of ImmuCell is .
When does ImmuCell pay dividends?
ImmuCell pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmuCell?
ImmuCell paid dividends every year for the past 0 years.
What is the dividend of ImmuCell?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmuCell located?
ImmuCell is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmuCell kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmuCell from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
When did ImmuCell pay the last dividend?
The last dividend was paid out on 7/31/2024.
What was the dividend of ImmuCell in the year 2023?
In the year 2023, ImmuCell distributed 0 USD as dividends.
In which currency does ImmuCell pay out the dividend?
The dividends of ImmuCell are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmuCell
Our stock analysis for ImmuCell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuCell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
